.png){kind=icon}
.png){kind=icon}
Return
Real-world progression-free survival 2 (PFS2) and tumor response of CDK4/ 6 inhibitors plus an aromatase inhibitor in patients with HR+/HER2-metastatic breast cancer in US routine clinical practice
.png){kind=icon}
OA
AI
R
B
R
L
L
M
C
E
F
C
T
X
DOI：10.1016/j.breast.2026.104780.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Background: Comparative cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) effectiveness data to date are limited to real-world progression-free survival (PFS) and overall survival. Additional effectiveness measures such as time from initial treatment to progression on first subsequent therapy (rwPFS2) and real-world tumor response (rwTR) provide full understanding of CDK4/6i real-world effectiveness. This analysis compared rwPFS2 and rwTR in patients with HR+/HER2- mBC receiving first-line (1L) CDK4/6i plus an aromatase inhibitor (AI) in US routine clinical practice. Patients and methods: P-VERIFY was a retrospective Flatiron Health Research Database analysis of adult patients with HR+/HER2- mBC who started 1L CDK4/6i (palbociclib; ribociclib; abemaciclib) plus AI between February 2015 and November 2023 (N = 9146). rwPFS2 analysis included all 9146 patients while rwTR analysis included 8010 (87.6%) patients who had >= 1 tumor response assessment. Stabilized inverse probability of treatment weighting (sIPTW) was used to balance patient baseline characteristics. A multivariable Cox proportional hazards model was used for sensitivity analysis. Results: After sIPTW, no significant differences were observed across all pairwise treatment comparisons between the CDK4/6i for rwPFS2 and rwTR (all p > 0.05). Findings were generally consistent across subgroups and sensitivity analyses. Findings were also consistent in a separate analysis of patients treated from 2017 onward, corresponding with commercial availability of all three CDK4/6i in the US. Conclusions: This real-world study demonstrated no statistically significant differences in rwPFS2 and rwTR in patients with HR+/HER2- mBC receiving 1L palbociclib, ribociclib, or abemaciclib, in combination with an AI, in routine clinical practice in the US. Clinicaltrials gov identifier: NCT06495164.
Keywords:
Breast cancer
Metastatic
CDK4/6i
Abemaciclib
Ribociclib
Palbociclib
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
7.9
Papers:
7.2K
Citations:
8.2K
Organization
Cited Papers